MBX Biosciences, Inc. Common Stock (MBX) EBITDA Margin: History & Chart

MBX Biosciences, Inc. Common Stock(MBX)

Biotechnology · Carmel, IN

$56.92-1.62 (-2.77%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Carmel, IN

63 employees

mbxbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Steve Hoerter

View full financials

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
MBX Biosciences, Inc. Common Stock (MBX)	$2.71B	N/A	N/A	N/A	N/A
Acadia Healthcare Company, Inc. (ACHC)vs ›	$2.70B	17.42%	19.36%	20.74%	18.34%
Precigen, Inc. (PGEN)vs ›	$2.69B	-1067.75%	-2196.34%	-1532.38%	-1148.77%
AtriCure, Inc. (ATRC)vs ›	$2.73B	3.20%	-0.69%	-3.43%	-1.09%
Aveanna Healthcare Holdings Inc. (AVAH)vs ›	$2.66B	11.88%	11.88%	7.44%	-2.29%
TransMedics Group, Inc. (TMDX)vs ›	$2.77B	22.42%	17.70%	-0.76%	-37.34%
Neogen Corporation (NEOG)vs ›	$2.61B	11.52%	13.31%	15.86%	16.56%
NewAmsterdam Pharma Company N.V. (NAMS)vs ›	$2.60B	-1001.92%	-694.29%	-672.56%	-672.56%
Beam Therapeutics Inc. (BEAM)vs ›	$2.60B	-270.04%	-444.88%	-365.27%	-89273.54%
Privia Health Group, Inc. (PRVA)vs ›	$2.56B	2.08%	1.74%	1.01%	-2.48%

NAME

MARKET CAP

EBITDA MARGIN

TTM

MBX Biosciences, Inc. Common Stock (MBX)

$2.71B

N/A

Acadia Healthcare Company, Inc. (ACHC)vs ›

$2.70B

17.42%

19.36%

20.74%

18.34%

Precigen, Inc. (PGEN)vs ›

$2.69B

-1067.75%

-2196.34%

-1532.38%

-1148.77%

AtriCure, Inc. (ATRC)vs ›

$2.73B

3.20%

-0.69%

-3.43%

-1.09%

Aveanna Healthcare Holdings Inc. (AVAH)vs ›

$2.66B

11.88%

7.44%

-2.29%

TransMedics Group, Inc. (TMDX)vs ›

$2.77B

22.42%

17.70%

-0.76%

-37.34%

Neogen Corporation (NEOG)vs ›

$2.61B

11.52%

13.31%

15.86%

16.56%

NewAmsterdam Pharma Company N.V. (NAMS)vs ›

$2.60B

-1001.92%

-694.29%

-672.56%

Beam Therapeutics Inc. (BEAM)vs ›

$2.60B

-270.04%

-444.88%

-365.27%

-89273.54%

Privia Health Group, Inc. (PRVA)vs ›

$2.56B

2.08%

1.74%

1.01%

-2.48%

EBITDA Margin: N/A

MBX EBITDA Margin Metrics

MBX Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

Related Metrics